People
Leaders from all over the world met for a virtual summit on Monday, May 4 to pledge billions of dollars to fund development of a vaccine against COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. Noticeably absent was the United States.
“We are very disappointed in the topline results in the STARS study that did not meet the study endpoints,” said Ravi Anand, Newron’s chief medical officer.
While the biopharmaceutical industry is working frantically to develop the tests, vaccines and therapeutics to combat COVID-19, the people doing the work are pushing their fears to one side. But, when asked, they admit to concerns. Not suprisingly, they mirror the fears shared by much of the world.
Life sciences and pharma companies strengthen their leadership teams and board with this week’s Movers & Shakers.
A vaccine for COVID-19 is unlikely to be ready in 2020, according to biopharma professionals responding to the BioSpace Workplace Survey: The Impact of COVID-19 – Spring 2020. Only 25% of respondents thought a vaccine might be possible this year.
The COVID-19 pandemic has increased the pace of drug development and regulatory approval dramatically, accelerating activities in ways that shorten the time needed to deliver safe, effective therapeutics, vaccines and diagnostics to patients.
BioSpace spoke to Aurika Savickaite, RN, MSN, to learn more about the ventilator helmet initiative, NIV helmets, and how they can be used during this coronavirus pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
Disgraced pharmaceutical executive Martin Shkreli wants out of prison to help research a treatment for COVID-19, but federal prosecutors want him to remain behind bars for the duration of his sentence for fraud.
“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” said Anthony S. Fauci, director of NIAID. “What it has proven is that a drug can block this virus. This will be the standard of care.”
PRESS RELEASES